DSOs Are Rolling Up DSOs—But the Economics Are Uglier Than You Think

DSOs are rolling up smaller DSOs. The economics are uglier than you think. This is not consolidation. This is margin compression disguised as scale.

What's really happening: Large DSOs (Heartland, Aspen, Smile Brands) are acquiring smaller regional players. The goal isn't clinical excellence. It's reducing corporate overhead per location. Take a 5-practice DSO with $2M in central costs. Roll it into a 200-practice DSO. Suddenly that overhead drops from $400K per practice to $40K per practice. That's the math.

But here's the catch: The acquired practice doesn't see that savings. Instead, they see new compliance, new systems, new staff who don't know their patients. Plus increased standardization. You lose the ability to hire local, price local, market local. Reimbursement doesn't change. Costs do.

Why you should care: If you're a single practice, a DSO rollup looks like liquidity and reduced stress. It isn't. You're trading autonomy for a 2-3 percent efficiency gain that you won't see. The real winner is the DSO's PE partner, who now reports better margins to their fund.

Action: If approached by a DSO, model what "standard cost structure" actually means for your specific practice. Run the math on centralized labor, supplies, marketing. Don't assume the acquirer's systems save you anything.